Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes and age-related disorders, today highlights ...

Analysts project the U.S. diabetes market will surge past $75 billion by 2031, driven by advanced cell therapies and continuous glucose monitoring systems transforming patient care [3]. Regenerative ...

Baystreet.ca News Commentary – The longevity economy is entering a massive repricing event as researchers confirm that ...

SAN FRANCISCO--(BUSINESS WIRE)--Encellin, a biotechnology company developing a cell encapsulation platform with an initial focus on Type 1 Diabetes (T1D), announced the closing of a $9.9M financing ...

Issued on behalf of Avant Technologies Inc. Equity Insider News Commentary VANCOUVER, BC, Dec. /CNW/ — The cell therapy manufacturing sector reached a pivotal inflection point in late ...

Encellin Inc. has announced the closing of a US$9.9 million financing round that will support the company’s development of its cell encapsulation platform with an initial focus on type 1 diabetes.

Metastasis is leading cause of cancer death. The essential step of metastasis is invasion. The actin cytoskeleton plays a pivotal role in invasion and is closely linked to endocytosis process. We ...

In 2020, there were 2.3 million women diagnosed with breast cancer. Deaths related to cancer occur due to metastasis. In most types of solid tumors, spreading happens through collective migration, ...